DDInter1021 DDInter1628
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromocriptine
Bromocriptine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurasidone
Lurasidone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromocriptine
Bromocriptine {u} (Compound) downregulates {v} (Gene) CDC45
CDC45 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pindolol
Pindolol {u} (Compound) upregulates {v} (Gene) AMDHD2
AMDHD2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurasidone
Lurasidone {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromocriptine
Bromocriptine {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mexiletine
Mexiletine {u} (Compound) upregulates {v} (Gene) CNOT4
CNOT4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digitoxin
Digitoxin {u} (Compound) downregulates {v} (Gene) IRAK1
IRAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digitoxin
Digitoxin {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digitoxin
Digitoxin {u} (Compound) downregulates {v} (Gene) UMPS
UMPS {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine and Bromocriptine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine and Bromocriptine (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Ruxolitinib (Compound)
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) upregulates AMDHD2 (Gene) and AMDHD2 (Gene) is downregulated by Ruxolitinib (Compound)
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine and Bromocriptine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Mexiletine and Mexiletine (Compound) upregulates CNOT4 (Gene) and CNOT4 (Gene) is upregulated by Ruxolitinib (Compound)
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin (Compound) downregulates IRAK1 (Gene) and IRAK1 (Gene) is bound by Ruxolitinib (Compound)
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin (Compound) downregulates UMPS (Gene) and UMPS (Gene) is upregulated by Ruxolitinib (Compound)